Massimo Mannelli

List of Publications by Citations

191 papers	14,370 citations	54 h-index	118 g-index
194 ext. papers	16,622 ext. citations	6.8 avg, IF	5.58 L-index

#	Paper	IF	Citations
191	Guidelines for diagnosis and therapy of MEN type 1 and type 2. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 5658-71	5.6	1466
190	Phaeochromocytoma. *Lancet, The*, **2005**, 366, 665-75	40	1229
189	A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *Journal of the American College of Cardiology*, **2006**, 48, 2293-300	15.1	990
188	Biochemical diagnosis of pheochromocytoma: which test is best?. *JAMA - Journal of the American Medical Association*, **2002**, 287, 1427-34	27.4	792
187	Adjuvant mitotane treatment for adrenocortical carcinoma. *New England Journal of Medicine*, **2007**, 356, 2372-80	59.2	568
186	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 92-102		467
185	Integrated genomic characterization of adrenocortical carcinoma. *Nature Genetics*, **2014**, 46, 607-12	36.3	423
184	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nature Genetics*, **2011**, 43, 663-7	36.3	409
183	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. *Lancet Oncology, The*, **2009**, 10, 764-71	21.7	405
182	Renal damage in primary aldosteronism: results of the PAPY Study. *Hypertension*, **2006**, 48, 232-8	8.5	351
181	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*, **2017**, 31, 181-193	24.3	350
180	Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. *European Journal of Cancer*, **2012**, 48, 1739-49	7.5	228
179	Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1541-7	5.6	227
178	MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clinical Cancer Research*, **2012**, 18, 2828-37	12.9	226
177	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. *Clinical Chemistry*, **2011**, 57, 411-20	5.5	225
176	Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 1999-2008	5.6	224
175	Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. *Endocrine-Related Cancer*, **2004**, 11, 897-911	5.7	153

174	Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. *Clinical Chemistry*, **2005**, 51, 735-44	5.5	145
173	Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. *JAMA - Journal of the American Medical Association*, **2010**, 304, 2611-9	27.4	144
172	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). *Modern Pathology*, **2015**, 28, 807-21	9.8	142
171	Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2566-71	5.6	141
170	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. *Nature Reviews Endocrinology*, **2017**, 13, 233-247	15.2	140
169	Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. *Annals of Oncology*, **2015**, 26, 2119-25	10.3	134
168	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. *Endocrine-Related Cancer*, **2011**, 18, 97-111	5.7	127
167	Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. *Human Molecular Genetics*, **2013**, 22, 2169-76	5.6	120
166	Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. *Hypertension*, **2007**, 50, 424-31	8.5	120
165	Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. *Journal of the American Society of Nephrology: JASN*, **1999**, 10, 245-55	12.7	111
164	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. *Lancet Oncology, The*, **2014**, 15, 648-55	21.7	110
163	Phaeochromocytoma, new genes and screening strategies. *Clinical Endocrinology*, **2006**, 65, 699-705	3.4	109
162	Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. *Journal of Clinical Endocrinology and Metabolism* , **2007**, 92, 2784-92	5.6	108
161	Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5□reductase, explaining the need for personalized glucocorticoid and androgen replacement. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 161-71	5.6	104
160	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. *Endocrine-Related Cancer*, **2009**, 16, 391-400	5.7	101
159	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. *Hypertension*, **2018**, 71, 585-591	8.5	95
158	Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. *Journal of Oncology*, **2012**, 2012, 872713	4.5	88
157	Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 3903-11	5.6	83

156	Analysis of circulating microRNAs in adrenocortical tumors. *Laboratory Investigation*, **2014**, 94, 331-9	5.9	79
155	Genetic screening for pheochromocytoma: should SDHC gene analysis be included?. *Journal of Medical Genetics*, **2007**, 44, 586-7	5.8	76
154	Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. *European Journal of Endocrinology*, **2005**, 153, 307-15	6.5	76
153	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1358-1365	5.6	75
152	Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2093-100	5.6	67
151	Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. *Journal of Hypertension*, **2007**, 25, 1433-42	1.9	67
150	Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 375-84	5.6	65
149	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *Journal of Hypertension*, **2020**, 38, 1443-1456	1.9	62
148	Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 1332-9	5.6	62
147	Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. *Endocrine-Related Cancer*, **2012**, 19, 149-55	5.7	61
146	Subclinical phaeochromocytoma. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2012**, 26, 507-15	6.5	59
145	Adrenal masses in neoplastic patients: the role of laparoscopic procedure. *Surgical Endoscopy and Other Interventional Techniques*, **2001**, 15, 90-3	5.2	59
144	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 312-318	5.6	59
143	Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. *Journal of Clinical Endocrinology and*	5.6	58
142	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2367-2374	5.6	57
141	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 773-781	18.1	56
140	Management and treatment of pheochromocytomas and paragangliomas. *Annals of the New York Academy of Sciences*, **2006**, 1073, 405-16	6.5	55
139	Opposing effects of HIF1□and HIF2□on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. *International Journal of Cancer*, **2014**, 135, 2054-64	7.5	54

138	The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. *American Journal of Surgical Pathology*, **2013**, 37, 1433-40	6.7	54
137	Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. *Hypertension*, **2010**, 55, 83-9	8.5	54
136	PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics. *Journal of Molecular Diagnostics*, **2017**, 19, 575-588	5.1	51
135	Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. *Human Molecular Genetics*, **2009**, 18, 1860-8	5.6	50
134	Gene expression profiling of benign and malignant pheochromocytoma. *Annals of the New York Academy of Sciences*, **2006**, 1073, 541-56	6.5	50
133	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. *American Journal of Physiology - Endocrinology and Metabolism*, **2008**, 295, E1223-33	6	47
132	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3526-38	5.6	46
131	Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. *Endocrine-Related Cancer*, **2013**, 20, 537-50	5.7	45
130	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. *Clinical Cancer Research*, **2015**, 21, 3020-30	12.9	44
129	Progress in primary aldosteronism: present challenges and perspectives. *Hormone and Metabolic Research*, **2010**, 42, 374-81	3.1	42
128	Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1332-9	5.6	42
127	Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. *Hypertension*, **1998**, 31, 802-8	8.5	42
126	Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. *Journal of the American Heart Association*, **2017**, 6,	6	41
125	Endogenous dopamine (DA) and DA2 receptors: a mechanism limiting excessive sympathetic-adrenal discharge in humans. *Journal of Clinical Endocrinology and Metabolism*, **1988**, 66, 626-31	5.6	41
124	Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. *Endocrine-Related Cancer*, **2005**, 12, 263-72	5.7	40
123	In vivo evidence that endogenous dopamine modulates sympathetic activity in man. *Hypertension*, **1999**, 34, 398-402	8.5	40
122	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. *European Journal of Endocrinology*, **2017**, 176, 453-461	6.5	39
121	H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E1376-80	5.6	39

120	Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. *PPAR Research*, **2008**, 2008, 904041	4.3	37
119	Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 359-63	5.6	36
118	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. *Genetics in Medicine*, **2019**, 21, 705-717	8.1	36
117	DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 923-932	5.6	35
116	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. *Genetics in Medicine*, **2018**, 20, 1652-1662	8.1	33
115	Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. *Scientific Reports*, **2017**, 7, 5474	4.9	33
114	Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4616-22	5.6	33
113	Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 18493-8	11.5	32
112	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. *JAMA Oncology*, **2019**, 5, 1440-1447	13.4	31
111	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. *Theranostics*, **2019**, 9, 4946-4958	12.1	30
110	Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 3731-8	5.6	30
109	Metformin as a new anti-cancer drug in adrenocortical carcinoma. *Oncotarget*, **2016**, 7, 49636-49648	3.3	30
108	Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. *Journal of Clinical Endocrinology and Metabolism*, **1984**, 59, 74-8	5.6	29
107	Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. *Endocrine-Related Cancer*, **2010**, 17, 169-77	5.7	27
106	Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. *Kidney International*, **2012**, 82, 1215-22	9.9	27
105	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 3491-3498	5.6	24
104	Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 468-70	5.6	24
103	Perioperative management of pheochromocytoma/paraganglioma: is there a state of the art?. *Hormone and Metabolic Research*, **2012**, 44, 373-8	3.1	23

102	A study on human adrenal secretion. Measurement of epinephrine, norepinephrine, dopamine and cortisol in peripheral and adrenal venous blood under surgical stress. *Journal of Endocrinological Investigation*, **1982**, 5, 91-5	5.2	23
101	Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling. *Acta Neuropathologica*, **2013**, 126, 575-94	14.3	22
100	Yeast model for evaluating the pathogenic significance of SDHB, SDHC and SDHD mutations in PHEO-PGL syndrome. *Human Molecular Genetics*, **2013**, 22, 804-15	5.6	22
99	2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma. *Oncotarget*, **2015**, 6, 5695-706	3.3	22
98	Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 238-45	5.6	21
97	Genetics and biology of pheochromocytoma. *Experimental and Clinical Endocrinology and Diabetes*, **2007**, 115, 160-5	2.3	21
96	Dopamine D2 receptor gene expression and binding sites in adrenal medulla and pheochromocytoma [published erratum appears in J Clin Endocrinol Metab 1994 Oct;79(4):1165]. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 79, 56-61	5.6	21
95	New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer. *Oncotarget*, **2017**, 8, 65525-65533	3.3	21
94	SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. *Journal of Nuclear Medicine*, **2003**, 44, 1057-64	8.9	21
93	Uncommon clinical presentations of pheochromocytoma and paraganglioma in two different patients affected by two distinct novel VHL germline mutations. *Clinical Endocrinology*, **2008**, 68, 762-8	3.4	20
92	Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline Gene Mutation. *Anticancer Research*, **2017**, 37, 805-812	2.3	20
91	The microenvironment induces collective migration in -silenced mouse pheochromocytoma spheroids. *Endocrine-Related Cancer*, **2017**, 24, 555-564	5.7	19
90	Variable expression of the transcription factors cAMP response element-binding protein and inducible cAMP early repressor in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 5443-9	5.6	19
89	Diagnostic problems in pheochromocytoma. *Journal of Endocrinological Investigation*, **1989**, 12, 739-57	5.2	19
88	Klinefelter's syndrome: a study of its hormonal plasma pattern. *Journal of Endocrinological Investigation*, **1978**, 1, 149-54	5.2	19
87	DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas. *European Journal of Endocrinology*, **2018**, 178, R11-R17	6.5	18
86	Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function. *Endocrine-Related Cancer*, **2015**, 22, 409-17	5.7	18
85	Centrally mediated effects of bromocriptine on cardiac sympathovagal balance. *Hypertension*, **2001**, 38, 123-9	8.5	18

84	A nonsecreting pheochromocytoma presenting as an incidental adrenal mass. Report on a case. *Journal of Endocrinological Investigation*, **1993**, 16, 817-22	5.2	18
83	Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma. *Journal of Endocrinological Investigation*, **1987**, 10, 377-82	5.2	18
82	Functional and in silico assessment of MAX variants of unknown significance. *Journal of Molecular Medicine*, **2015**, 93, 1247-55	5.5	17
81	Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation. *Hormones and Cancer*, **2014**, 5, 174-84	5	17
80	Mitochondrial function and content in pheochromocytoma/paraganglioma of succinate dehydrogenase mutation carriers. *Endocrine-Related Cancer*, **2012**, 19, 261-9	5.7	17
79	Opioid modulation of normal and pathological human chromaffin tissue. *Journal of Clinical Endocrinology and Metabolism*, **1986**, 62, 577-82	5.6	17
78	Effects of naloxone on catecholamine plasma levels in adult men. A dose-response study. *European Journal of Endocrinology*, **1984**, 106, 357-61	6.5	17
77	Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 1712-1724	5.6	17
76	Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes. *Gene*, **2014**, 536, 332-5	3.8	16
75	Xenograft models for preclinical drug testing: implications for adrenocortical cancer. *Molecular and Cellular Endocrinology*, **2012**, 351, 71-7	4.4	16
74	Role of the PPAR-β system in normal and tumoral pituitary corticotropic cells and adrenal cells. *Neuroendocrinology*, **2010**, 92 Suppl 1, 23-7	5.6	16
73	Bilateral massive adrenal hemorrhage due to sepsis: report of two cases. *Journal of Endocrinological Investigation*, **1994**, 17, 821-4	5.2	16
72	Human fetal adrenal cells retain age-related stem- and endocrine-differentiation potential in culture. *FASEB Journal*, **2019**, 33, 2263-2277	0.9	16
71	Dissecting the origin of inducible brown fat in adult humans through a novel adipose stem cell model from adipose tissue surrounding pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E1903-12	5.6	15
70	Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. *Journal of the Autonomic Nervous System*, **1998**, 74, 152-9		15
69	The Y606C RET mutation causes a receptor gain of function. *Clinical Endocrinology*, **2008**, 69, 253-8	3.4	15
68	Presence of dopamine-dependent adenylate cyclase activity in human renal cortex. *European Journal of Pharmacology*, **1988**, 149, 351-6	5.3	15
67	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. *Cancers*, **2020**, 12,	6.6	14

66	Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. *European Journal of Endocrinology*, **2015**, 173, 43-52	6.5	14
65	Incidental and metastatic adrenal masses. *Seminars in Oncology*, **2010**, 37, 649-61	5.5	14
64	Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 79, 590-594	5.6	14
63	Effects of acute clonidine administration on power spectral analysis of heart rate variability in healthy humans. *Autonomic and Autacoid Pharmacology*, **1998**, 18, 307-12		14
62	Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension. *American Journal of Hypertension*, **1995**, 8, 799-807	2.3	13
61	Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature. *Archives of Endocrinology and Metabolism*, **2017**, 61, 90-97	2.2	12
60	Handgrip-induced airway dilation in asthmatic patients with bronchoconstriction induced by MCh inhalation. *Journal of Applied Physiology*, **2002**, 93, 1723-30	3.7	12
59	Does endogenous dopamine modulate human sympathetic activity through DA2 receptors?. *European Journal of Clinical Pharmacology*, **1985**, 29, 159-64	2.8	12
58	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. *Nature Reviews Endocrinology*, **2021**, 17, 435-444	15.2	12
57	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. *Cell and Tissue Research*, **2018**, 374, 473-485	4.2	12
56	Cushing's syndrome in pregnancy. *Gynecological Endocrinology*, **2015**, 31, 102-4	2.4	11
55	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. *Journal of Pathology*, **2020**, 251, 378-387	9.4	11
54	Seladin-1 expression is regulated by promoter methylation in adrenal cancer. *BMC Cancer*, **2010**, 10, 201	4.8	11
53	Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. *Oncotarget*, **2015**, 6, 39111-26	3.3	11
52	Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. *Hepatology*, **1996**, 24, 1063-7	11.2	11
51	Pheochromocytoma crisis caused by contemporary ergotamine, caffeine, and nimesulide administration. *American Journal of the Medical Sciences*, **1997**, 314, 396-8	2.2	11
50	Regional differences of adenylate cyclase stimulation by calcitonin and calcitonin gene-related peptide in the human kidney. *Journal of Clinical Endocrinology and Metabolism*, **1989**, 69, 491-5	5.6	10
49	Rare diseases in clinical endocrinology: a taxonomic classification system. *Journal of Endocrinological Investigation*, **2015**, 38, 193-259	5.2	9

48	SDH mutations in patients affected by paraganglioma syndromes: a personal experience. *Annals of the New York Academy of Sciences*, **2006**, 1073, 183-9	6.5	9
47	Adrenal incidentaloma: the influence of a decision-making algorithm on the short-term outcome of laparoscopy. *Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A*, **2005**, 15, 451-9	2.1	8
46	The Adipose Stem Cell as a Novel Metabolic Actor in Adrenocortical Carcinoma Progression: Evidence from an In Vitro Tumor Microenvironment Crosstalk Model. *Cancers*, **2019**, 11,	6.6	8
45	Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension. *Frontiers in Endocrinology*, **2019**, 10, 333	5.7	7
44	Pitfalls in genetic analysis of pheochromocytomas/paragangliomas-case report. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 2321-6	5.6	7
43	A case of hyponatremia caused by central hypocortisolism. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 369-75		7
42	Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocytomas. *Journal of Endocrinological Investigation*, **1988**, 11, 133-8	5.2	7
41	Effects of thyroid replacement therapy on catecholamine plasma levels. *Journal of Endocrinological Investigation*, **1983**, 6, 307-9	5.2	7
40	The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas. *Neuroendocrinology*, **2017**, 105, 384-393	5.6	6
39	Prognostic and Monitoring Value of Circulating Tumor Cells in Adrenocortical Carcinoma: A Preliminary Monocentric Study. *Cancers*, **2020**, 12,	6.6	6
38	A further case of giant intrasellar carotid aneurysm mimicking a pituitary adenoma: the relevance of a multivariate approach in differential diagnosis. *Italian Journal of Neurological Sciences*, **1994**, 15, 369-72		6
37	Adrenal medulla secretion in Cushing's syndrome. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 78, 1331-1335	5.6	6
36	15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma. *Endocrine-Related Cancer*, **2015**, 22, T83-90	5.7	5
35	Adrenocortical carcinoma: current treatment options. *Current Opinion in Oncology*, **2021**, 33, 16-22	4.2	5
34	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. *Frontiers in Endocrinology*, **2019**, 10, 487	5.7	4
33	Feasibility and safety of minimal-incision thyroidectomy for Graves' disease: a prospective, single-center study. *Head and Neck*, **2013**, 35, 1345-8	4.2	4
32	Mapping of human autoantibody epitopes on aromatic L-amino acid decarboxylase. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1096-105	5.6	4
31	Klinefelter's syndrome: effects of short-term testosterone administration on hypothalamic-pituitary axis function. *Journal of Endocrinological Investigation*, **1978**, 1, 239-44	5.2	4

30	The Role of Metabolic Changes in Shaping the Fate of Cancer-Associated Adipose Stem Cells. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 332	5.7	3
29	Biochemistry, genetics and therapy of malignant pheochromocytomas. *Annales D'Endocrinologie*, **2009**, 70, 166-7	1.7	3
28	Naloxone administration does not affect gonadotrophin secretion in male patients with isolated hypogonadotrophic hypogonadism. *European Journal of Endocrinology*, **1985**, 109, 153-7	6.5	3
27	Urinary endothelin-1 excretion is enhanced by low-dose infusion of brain natriuretic peptide in normal humans. *Hypertension*, **1997**, 29, 70-4	8.5	3
26	Role for endogenous dopamine in modulating sympathetic-adrenal activity in humans. *Hypertension Research*, **1995**, 18 Suppl 1, S79-86	4.7	3
25	A case of malignant insulinoma responsive to somatostatin analogs treatment. *BMC Endocrine Disorders*, **2018**, 18, 98	3.3	3
24	Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas. *Frontiers in Endocrinology*, **2012**, 3, 65	5.7	2
23	Dopamine modulation of pathological human chromaffin tissue. *American Journal of Hypertension*, **1990**, 3, 22S-24S	2.3	2
22	Analysis of Telomere Maintenance Related Genes Reveals as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. *Cancers*, **2021**, 13,	6.6	2
21	Diagnosis and Clinical Pictures **2013**, 35-53		1
20	Il dosaggio delle metanefrine nella diagnosi del feocromocitoma: vantaggi clinici e problematiche di laboratorio. *L Endocrinologo*, **2010**, 11, 65-74	0	1
19	Vasoactive factors in the mechanism of renal sodium handling in cirrhotics: the effect of acute plasma expansion. *Pharmacological Research Communications*, **1984**, 16, 613-35		1
18	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. *Cancers*, **2021**, 13,	6.6	1
17	and Non-Chromaffin Tumors: A Mediastinal Germ Cell Tumor Occurring in a Young Man with Germline Mutation. *Medicina (Lithuania)*, **2020**, 56,	3.1	1
16	Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer. *Frontiers in Endocrinology*, **2021**, 12, 698862	5.7	1
15	Functional significance of germline EPAS1 variants. *Endocrine-Related Cancer*, **2021**, 28, 97-109	5.7	1
14	Germline Mutation in Gene Associated with Loss of Heterozygosity: Usefulness of Next-Generation Sequencing in the Genetic Screening of Patients with Pheochromocytoma. *International Journal of Endocrinology*, **2020**, 2020, 3671396	2.7	0
13	SDHB and SDHD silenced pheochromocytoma spheroids respond differently to tumour microenvironment and their aggressiveness is inhibited by impairing stroma metabolism.. *Molecular and Cellular Endocrinology*, **2022**, 547, 111594	4.4	0

12	Malignant Pheochromocytoma **2019**, 460-468	
11	Metodiche di dosaggio di metanefrine e catecolamine: rischi e variabili interpretative per i dosaggi effettuati in centri non specializzati. *L Endocrinologo*, **2016**, 17, 107-108	0
10	La Fascina-1 un nuovo biomarker prognostico associato all'invasivit del carcinoma corticosurrenalico. *L Endocrinologo*, **2019**, 20, 392-393	0
9	Detection of circulating tumor cells in adrenocortical neoplasms. *Pathology*, **2014**, 46, S13-S14	1.6
8	Sindromi feocromocitoma/paraganglioma familiari. *L Endocrinologo*, **2009**, 10, 26-31	0
7	Renal effects of atrial natriuretic peptide during dopa-decarboxylase inhibition in patients with essential hypertension. *European Journal of Clinical Pharmacology*, **1993**, 44, 423-7	2.8
6	Impaired cerebral autoregulation in patients with shy-drager syndrome. *International Journal of Angiology*, **1993**, 2, 12-15	1.1
5	The Endocrine Regulation of Blood Pressure. *Endocrinology*, **2018**, 611-625	0.1
4	The Endocrine Regulation of Blood Pressure. *Endocrinology*, **2016**, 1-15	0.1
3	Le crisi di un anziano signore. *L Endocrinologo*, **2020**, 21, 303-304	0
2	Commentary. *Clinical Chemistry*, **2016**, 62, 929	5.5
1	Caratterizzazione genomica del carcinoma surrenalico. *L Endocrinologo*, **2016**, 17, 293-299	0